Trial Information

Summary: An Open Label, Single Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma

You have been asked to participate in this research study because you have a hematological malignancy (cancer of the blood) called multiple myeloma. The purpose of this study is to evaluate the safety and effectiveness of an investigational (not approved by the Food and Drug Administration (FDA)) drug called carfilzomib in subjects with multiple myeloma who have previously received the medication bortezomib with either thalidomide or lenalidomide.  Your treatment on this study is expected to last at least 2 months (two 4-week cycles of treatment).  You will continue to receive treatment for as long as you continue to do well on the medication for up to 12 total cycles.  After your treatment on this study is over, your medical condition will continue to be followed for a minimum of 4 weeks.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 2, 2008 at 2:51:05 PM